timothy sykes logo
Hologic’s Share Surge Amidst Acquisition Talks With Blackstone and TPG Thumbnail
G Google News

Hologic’s Share Surge Amidst Acquisition Talks With Blackstone and TPG

BRYCE TUOHEY•UPDATED JUN. 15, 2026, 5:24 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Hologic Inc.’s stocks have been trading up by 7.45 percent following optimistic investor sentiment from promising news.

Key Highlights

  • Acquisition talks between Hologic and private equity giants Blackstone and TPG are reportedly advanced, with the deal valuing the company at more than $17 billion. This news comes as Hologic’s stock surged 6% to $73.92, reflecting increased investor confidence in the company’s future prospects.
  • The company’s price target was raised by Evercore ISI to $78, following an upgrade to Outperform from In Line. This suggests enhanced market expectations for Hologic’s performance and potential growth.
  • Hologic received FDA clearance and CE marking in the European Union for its Panther Fusion gastrointestinal and expanded bacterial assays, adding to its portfolio of diagnostic solutions and strengthening its market position in the medical technology sector.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: Hologic Inc. (HOLX) holds a solid position in the healthcare industry, with a commendable gross margin of 51.8% and an impressive ebitda margin of 25.2%. The company demonstrates robust profitability evidenced by a profit margin of 13.79% from continuing operations. A critical insight from the income statement reveals a slight decline in three-year revenue growth at -8.23%, yet a more encouraging five-year trajectory at 4.15%. Hologic’s prudent financial management is mirrored in its healthy debt metrics, with a total debt-to-equity ratio of 0.52 and a current ratio of 3.6, indicating strong liquidity. The price-to-earnings ratio (P/E) of 28.42 is competitive, aligning with industry benchmarks, suggesting an alignment of market expectations with Hologic’s earning potential. However, the subdued returns on assets (6.3%) and equity (11.38%) suggest room for operational enhancements to maximize investor returns.

  2. Technical Analysis & Trading Strategy: Recent weekly price patterns for Hologic reveal a notable uptrend, with prices escalating from an opening of $65.51 on October 13, 2025, to a close of $73.6 on October 17, 2025. This bullish movement is supported by high volume on the significant October 17 surge, strongly influenced by acquisition talks. The dominant trend showcases an upward momentum, with a bullish engulfing pattern marking the week’s end, signaling probable price continuation. Traders are advised to capitalize on this uptrend, potentially targeting $75 as a resistance level, using $69 as a support level. Given the increasing volume patterns aligning with critical price levels, a buy strategy with cautious stop-loss settings just below the $69 support level should be considered to mitigate downside risk.

  3. Catalysts & Outlook: Recent developments strengthen Hologic’s growth prospects. The potential acquisition by Blackstone and TPG, appraising the firm at over $17 billion, serves as a robust catalyst for investor sentiment, as underscored by the stock’s 6% surge. Simultaneously, the FDA clearance and CE mark achievements for gastrointestinal assays expand Hologic’s market reach and add momentum to its innovation narrative. Analysts’ upgrades and raised price targets further underline optimism around Hologic’s earnings potential, positioning the stock favorably against healthcare sector benchmarks. With these catalysts, the stock demonstrates a bullish trajectory, with a newly established resistance level at $78, as indicated by recent analyst forecasts. In conclusion, Hologic’s advanced product offerings and strategic alignments suggest a promising outlook in the near term.

Candlestick Chart

More Breaking News

Weekly Update Oct 13 – Oct 17, 2025: On Saturday, October 18, 2025 Hologic Inc. stock [NASDAQ: HOLX] is trending up by 7.45%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Hologic’s financial metrics reveal solid growth and performance. The company’s profitability ratios, including a gross margin of 51.8% and a pretax profit margin of 28.6%, indicate efficient cost management and strong operational execution. Despite a recent dip in revenue over the past three years by 8.23%, there’s a 4.15% growth over five years, reflecting a longer-term positive trajectory.

The stock’s recent movement, highlighted by a closing price jump to $73.6 from $69.78, mirrors market optimism bolstered by strategic advancements and positive financial indicators. With an enterprise value of over $16 billion and a reasonable PE ratio of 28.42, Hologic presents itself as a valuable player in its industry.

Cash flow indicators are robust, with a remarkable $343.3 million operating cash flow, and a free cash flow of $308.5 million, signaling strong liquidity and the capacity for future investment in growth opportunities. Furthermore, the company’s strategic move of partnering with Minicarm.com for distributing the Fluoroscan Insight FD Mini C-Arm enhances operational efficiency by reducing direct commercial overhead.

Conclusion

Hologic’s recent strategic maneuvers—including acquisition discussions, market expansion, and technological advancements—underscore the company’s commitment to innovation and growth. As it navigates through significant corporate actions, the outlook remains bullish with increasing trader confidence reflected in stock performance and favorable analyst ratings. In the trading world, as millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This mindset reinforces Hologic’s strategic focus on sustainable growth. The current developments position Hologic well to capitalize on opportunities in the evolving healthcare landscape, potentially yielding significant long-term shareholder returns.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”